

## SAFETY DATA SHEETS

**This SDS packet was issued with item:**

078940499

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

078940498 078940500 078940501

# SAFETY DATA SHEET


## Bravecto®

Page 1 of 5

### Section 1: Identification of the Substance and Supplier

<b>Product name</b>	<b>Bravecto</b>  This SDS relates to the following marketed products:  <b>Bravecto for Very Small Dogs (2 - 4.5 kg)</b> <b>Bravecto for Small Dogs (&gt;4.5 - 10 kg)</b> <b>Bravecto for Medium-Sized Dogs (&gt;10 - 20 kg)</b> <b>Bravecto for Large Dogs (&gt;20 - 40 kg)</b> <b>Bravecto for Extra Large Dogs (&gt;40 - 56 kg)</b>
<b>Recommended use</b>	For oral flea and tick treatment in dogs
<b>Company details</b>	<b>Schering-Plough Animal Health Limited</b> <b>33 Whakatiki Street, Upper Hutt 5018, New Zealand</b>  <b>Phone: 0800 800 543 Fax: 0800 808 100</b> <b>Website: <a href="http://www.msd-animal-health.co.nz">www.msd-animal-health.co.nz</a></b> <b>Hours: 8 am – 5 pm, Mon – Fri</b>
<b>Emergency telephone</b>	<b>0800 764 766 (0800 POISON) 24 hours human health</b> <b>0800 243 622 (0800 CHEMCALL) 24 hours</b>
<b>Date of preparation</b>	April 2019

### Section 2: Hazards Identification

<b>Hazard classifications</b>	6.1E: Acute toxicant 6.3B: Skin irritant 9.1A: Aquatic ecotoxicant
<b>GHS Pictogram:</b>	
<b>Signal word</b>	Warning
<b>Hazard statement</b>	H303: May be harmful if swallowed. H316: Causes mild skin irritation. H410: Very toxic to aquatic life with long lasting effects.
<b>Prevention statement</b>	P102: Keep out of reach of children. P103: Read label before use. P273: Avoid release to the environment.
<b>Response statement</b>	P101: If medical advice is needed, have product container or label at hand. P332 + P313: If skin irritation occurs: Get medical advice/ attention. P391: Collect spillage.
<b>Disposal</b>	P501: Dispose of product, packaging and waste at an approved landfill or other approved facility.

### Section 3: Composition/Information on Ingredients

Chemical name	CAS number	Concentration
Fluralaner	846731–61-3	13.64%
Sodium lauryl sulphate	151-21-3	<5 %
Disodium Pamoate	6640-22-8	<5 %

# SAFETY DATA SHEET

## Bravecto®

Page 2 of 5

### Section 4: First Aid Measures

#### Necessary first aid measures

**SKIN CONTACT** While wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.

**EYE CONTACT** Immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.

**INGESTION** Rinse mouth with water and drink a glass of water. DO NOT induce vomiting unless under the direction of a qualified medical professional or National Poisons Centre. If symptoms persist, consult a doctor.

**INHALATION** Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a doctor.

#### Required instructions

For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.

#### Workplace facilities

Emergency showers and eyewashes may be warranted depending on quantity and type of use.

### Section 5: Fire Fighting Measures

#### Type of hazard

Not classified as flammable

#### Fire hazard properties

Not applicable

#### Regulatory requirements

Not applicable

#### Extinguishing media and methods

Carbon dioxide (CO<sub>2</sub>), extinguishing powder or water spray.

#### Hazchem code

2X

#### Recommended protective clothing

Wear full protective clothing and self-contained breathing apparatus (SCBA).

### Section 6: Accidental Release Measures

#### Personal Precautions

Avoid contact with skin, eyes and clothing. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing.

#### Environmental Precautions

Prevent spilled material from flowing onto adjacent land or into streams, ponds, or lakes. Avoid release to the environment.

#### Emergency procedures

Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Recover and salvage product where possible. Otherwise sweep up and collect and place in sealable container for disposal. Seek advice from the local authority regarding disposal. Avoid contamination of any water source with product or empty container.

# SAFETY DATA SHEET

## Bravecto®

Page 3 of 5

### Section 7: Handling and Storage

<b>Precautions for safe handling</b>	Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.
<b>Regulatory requirements</b>	Signage required where quantities greater than 100 kg are present. Emergency Plan required where quantities greater than 100 kg are present.
<b>Handling practices</b>	Avoid contact with skin. Keep containers adequately sealed during material transfer, transport, or when not in use.
<b>Certified handlers</b>	Not required
<b>Conditions for safe storage</b>	Store in original container in a cool, dry, ventilated place away from direct heat or direct sunlight. Keep container sealed when not in use. Keep out of reach of children.
<b>Store site requirements</b>	Store below 30°C. Protect from humidity and light. DO NOT REFRIGERATE.
<b>Packaging</b>	PG III

### Section 8: Exposure Control/Personal Protection

<b>Occupational exposure limits</b>	No WES is set for this substance at this time.
<b>Application in the workplace</b>	Ensure adequate ventilation. Keep container sealed when not in use.
<b>Exposure standards outside the workplace</b>	No TEL or EEL is set for this substance at this time.
<b>Personal protection</b>	Wear chemical resistant gloves, facemask or goggles.
<b>Engineering controls</b>	The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

### Section 9: Physical and Chemical Properties

Appearance	Light to dark brown chewable tablet
Boiling Point	Not determined
Melting/Softening point	Not determined
Vapour Pressure	Not determined
Specific Gravity	Not determined
Solubility (H <sub>2</sub> O)	Not determined

# SAFETY DATA SHEET

## Bravecto®

Page 4 of 5

Percent Volatiles	Not determined
Flash Point	Not determined
Evaporation Rate	Not determined

### Section 10: Stability and Reactivity

<b>Stability of the substance</b>	Stable under normal conditions. No hazardous reactions known.
<b>Conditions to avoid</b>	Keep away from heat, sparks, open flame and direct sunlight.
<b>Material to avoid</b>	Avoid food products. Strong acids and bases. Strong oxidizers.
<b>Hazardous decomposition products</b>	No dangerous decomposition is expected if used according to manufacturer's specifications.

### Section 11: Toxicological Information

#### Acute effects for individual ingredients only

ORAL	Fluralaner: LD50 >2000 mg/kg (rat); Sodium lauryl sulphate: LD50 1288 mg/kg (rat)
DERMAL	Fluralaner: LD50 >2000 mg/kg (rat); Sodium lauryl sulphate: LD50 580 mg/kg (rabbit) (IUCLID)
<b>Disodium Pamoate:</b> Skin inflammation is characterized by itching, scaling, reddening, or, occasionally, blistering. Inflammation of the eye is characterized by redness, watering, and itching.	
TEL	No TEL is set for this substance at this time.

#### Chronic/long term effects for individual ingredients only

### Section 12: Environmental Information

#### Effects for individual ingredients only

AQUATIC	Fluralaner: 96-hr LC50 (Common carp): 2 mg/L 48-hr EC50 (Daphnia magna): 0.0001 - 0.01 mg/L 72-hr EC50 (P. subcapitata): >10 mg/L
TERRESTRIAL INVERTEBRATES	No data
EEL	No EEL is set for this substance at this time.

### Section 13: Disposal Considerations


<b>Disposal information</b>	<b>Disposal</b> Dispose of unused contents in a suitable landfill. Where possible, dispose of unused product through AgRecovery Chemicals. Avoid contamination of any water source or the environment with product or empty container.  <b>Container Disposal</b> Dispose of empty container by puncturing and burying in a suitable landfill. Where possible, recycle through AgRecovery. Do NOT burn.
<b>Reference</b>	Current version of NZS 8409 Management of Agrichemicals

# SAFETY DATA SHEET

## Bravecto®

Page 5 of 5

### Section 14: Transport Information

<b>UN Number</b>	3077
<b>UN proper shipping name</b>	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Isoxazoline derivative – Fluralaner)
<b>UN dangerous goods class and subsidiary risk</b>	9
<b>UN Packaging Group</b>	PG III
<b>Environmental hazards</b>	Marine pollutant
<b>Special precautions when transporting the substance</b>	

### Section 15: Regulatory Information

<b>Regulatory status</b>	ACVM Registration No: A11019 For conditions of registration see <a href="http://www.foodsafety.govt.nz">www.foodsafety.govt.nz</a>  HSNO Approval Code: HSR100757. For a full listing of controls see <a href="http://www.epa.govt.nz">www.epa.govt.nz</a>
--------------------------	--

### Section 16: Other Information

<b>Additional information</b>	Bravecto is a registered trademark.
-------------------------------	-------------------------------------

Schering-Plough Animal Health Ltd known as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Schering-Plough Animal Health Limited urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Schering-Plough Animal Health Ltd extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).